Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat

Kidney International

Volumn 57, Issue 5, 2000, Pages 1882-1894

  Kelly, Darren J ^a,b   Skinner, Sandford L ^a,b   Gilbert, Richard E ^a,b   Cox, Alison J ^a,b   Cooper, Mark E ^a,b   Wilkinson Berka, Jennifer L ^a,b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Diabetic nephropathy; Endothelin; Glomerulosclerosis; Hypertension; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BOSENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT;

EID: 0034021275     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00038.x     Document Type: Article

References (44)

1. 1. COOPER ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352:213-219, 1998
2. 2. ANDERSON S, RENNKE HG, GARCIA DL, BRENNER BM: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36:526-536, 1989
3. 3. ALLEN TJ, CAO Z, YOUSSEF S, HULTHEN UL, COOPER ME: The role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies. Diabetes 46:1612-1618, 1997
4. 4. LEWIS ES, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
5. 5. ZATZ R, DUNN R, MEYER TW, ANDERSON S, RENNKE HG, BRENNER BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
6. 6. ANDERSON S, JUNG FF, INGELFINGER JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J PhysioL 265:F477-F486, 1993
7. 7. HAN DC, ISONO M, HOFFMAN BB, ZIYADEH FN: High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: Mediation by autocrine activation of TGF-beta? J Am Soc Nephrol 10:91891-91899, 1999
8. 8. ROCCO M, CHEN Y, GOLDFARB S, ZIYADEH FN: Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 41:107-114, 1992
9. 9. ARIMA S, ITO S, OMATA K, TAKEUCHI K, ABE K: High glucose augments angiotensin II action by inhibiting NO synthesis in in vitro microperfused rabbit afferent arterioles. Kidney Int 48:683-689, 1995
10. 10. SHARMA K, ZIYADEH FN: Hyperglycaemia and diabetic kidney disease: The case for transforming growth factor-beta as a key mediator. Diabetes 44:1139-1146, 1998
11. 11. BENIGNI A, REMUZZI G: Mechanism of progression of renal disease-growth factors and related mechanisms. J Hypertens 16(Suppl):S9-S12, 1998
12. 12. GILBERT RE, COX A, WU LL, ALLEN TJ, HULTHEN L, JERUMS G, COOPER ME: Expression of transforming growth factor-beta and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of angiotensin converting enzyme inhibition. Diabetes 47:414-422, 1998
13. 13. WU L, ROE C, COX A, DZIADEK M, COOPER ME, GILBERT RE: Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 51:1553-1567, 1997
14. 14. KAGAMI S, BORDER WA, MILLER DE, NOBLE NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
15. 15. MULLINS JJ, PETERS J, GANTEN D: Fulminant hypertension intransgenic rats harbouring the mouse Ren-2 gene. Nature 344:541-544, 1990
16. 16. KELLY DJ, WILKINSON-BERKA JL, COOPER ATJ, ME, SKINNER SL: A new model of progressive diabetic renal impairment in the transgenic (mRen-2)27 rat. Kidney Int 54:343-352, 1998
17. 17. RUIZ ORTEGA M, GOMEZ GARRE D, ALCAZAR R, PALACIOS I, BUSTOS C, GONZALEZ S, PLAZA J, GONZALEZ E, EGIDO J: Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens S51-S58, 1994
18. 18. FUKUI M, NAKAMURA T, EBIHARA I, OSADA S, TOMINO Y, MASAKI T, GOTO K, FURUICHI Y, KOIDE H: Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 122:149-156, 1993
19. 19. FUKUI M, NAKAMURA T, EBIHARA I, MAKITA Y, OSADA S, TOMINO Y, KOIDE H: Effects of enalapril on endothelin-1 and growth factor gene expression in diabetic rat glomeruli. J Lab Clin Med 123:763-768, 1994
20. 20. BENIGNI A, ZOJA C, CORNA D, ORISIO S, LONGARETTI L, BERTANI T, REMUZZI G: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44:440-444, 1993
21. 21. BENIGNI A, COLOSIO W, BRENA C, BRUZZI I, BERTANI T, REMUZZI G: Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47:450-456, 1998
22. A-receptor antagonist. Circulation 96:1593-1597, 1997
23. 23. SOULIS T, COOPER ME, VRANES D, BUCALA R, JERUMS G: The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 50:627-634, 1996
24. 24. ALLEN TJ, COOPER ME, O'BRIEN RC, BACH LA, JACKSON B, JERUMS G: Glomerular filtration rate in the streptozotocin diabetic rat: The role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes 38:1182-1190, 1990
25. 25. BERKA JLA, ALCORN D, RYAN G, SKINNER SL: Renin processing studied by immunogold localisation of prorenin and renin in granular juxtaglomerular cells in mice treated with enalapril. Cell Tissue Res 268:141-148, 1992
26. 26. BRADBURY P, GORDON KC, COOK HC: Connective tissues and stains, in Theory and Practice of Histological Techniques (vol 1, 2nd ed), edited by BANCROFT JD, STEVENS A, London, Churchill Livingstone, 1982, pp 122-216
27. 27. SAITO T, SUMITHRAN E, GLASGOW EF, ATKINS RC: The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 32:691-699, 1987
28. 28. RONG P, BERKA JL, KELLY DJ, ALCORN D, SKINNER SL: Renin processing and secretion in adrenal and retina of transgenic (mRen-2)27 rats. Kidney Int 46:1583-1587, 1994
29. 29. CAMPBELL DJ, VALENTIJN AJ, BERKA JL: Production of rat renin fusion protein in Escherichia coli and the preparation of renin-specific antisera. Mol Cell Endocrinol 73:83-91, 1990
30. 30. GILBERT RE, VRANES D, BERKA JL, KELLY DJ, COX A, WU LL, STACKER SA, COOPER ME: Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 78:1-11, 1998
31. 31. COOPER ME, ALLEN TJ, MACMILLAN PA, CLARKE BA, JERUMS G, DOYLE AE: Enalapril retards albuminuria and glomerular basement membrane thickening in experimental diabetic nephropathy. Diabetologia 32:326-328, 1989
32. 32. COOPER ME, ALLEN TJ, O'BRIEN RC, PAPAZOGLOU D, CLARKE B, JERUMS G, DOYLE AE: Nephropathy in a model combining genetic hypertension with experimental diabetes: Enalapril versus hydralazine and metoprolol therapy. Diabetes 39:1575-1579, 1990
33. 33. GARDINER SM, MARCH PA, KEMP JJ, MULLINS JJ, BENNETT T: Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27) hypertensive rats. Br J Pharmacol 2244:2237, 1995
34. 34. BALAKRISHNAN SM, WANG HD, GOPALAKRISHNAN V, WILSON TW, MCNEIL JR: Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension 28:806-809, 1996
35. 35. CAMPBELL DJ, KELLY DJ, WILKINSON-BERKA JL, COOPER ME, SKINNER SL: Increased bradykinin and normal angiotensin peptide levels in streptozotocin-diabetic Sprague-Dawley and TGR (mRen-2)27 rats. Kidney Int 56:211-221, 1999
36. 36. HUNLEY TE, FOGO A, IWASAKI S, KON V: Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 5:1718-1723, 1995
37. 37. HARRIS RD, STEFFES MW, BILOUS RW, SUTHERLAND DE, MAUER SM: Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int 40:107-114, 1991
38. 38. OSTERBY R, PARVING HH, NYBERG G, HOMMEL E, JORGENSEN HE, LOKKEGAARD H, SVALANDER C: A strong correlation between glomerular filtration rate and filtration surface in diabetic nephropathy. Diabetologia 31:265-270, 1988
39. B receptors. Mol Cell Biochem 154:31-37, 1996
40. 40. KING AJ, BRENNER BM, ANDERSON S: Endothelin: A potent renal and systemic vasoconstrictor peptide. Am J Physiol 256:F1051-F1058, 1989
41. 41. LIN H, SANGMAL M, SMITH MJ, YOUNG DB: Effect of endothelin-1 on glomerular hydraulic pressure and renin release in dogs. Hypertension 21:845-851, 1993
42. 42. DLUGOSZ JA, MUNK S, ZHOU XP, WHITESIDE CI: Endothelin-1-induced mesangial cell contraction involves activation of protein kinase c-alpha-delta, and -epsilon. Am J Physiol 44:423-432, 1998
43. 43. AYO SH, RADNIK RA, GLASS WFD, GARONI JA, RAMPT ER, APPLING DR, KREISBERG JI: Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am J Physiol 260:F185-F191, 1991
44. 44. ZHANG SL, FILEP JG, HOHMAN TC, TANG SS, INGELFINGER JR, CHAN JSD: Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 55:454-464, 1999